Peptides · Peptide comparison
Survodutide vs Tirzepatide
Dual GLP-1/glucagon receptor agonist for obesity and metabolic liver disease
The dual-action powerhouse that targets both GIP and GLP-1 receptors, delivering the most dramatic weight loss results ever seen in a medication—averaging over 20% body weight reduction while also crushing blood sugar levels in people with diabetes.
- Weight Management
- Weight Management
At a glance
Quick comparison
Efficacy
Benefit ratings
Weight Management
Metabolic Health
Blood Sugar Control
Weight Loss
Appetite Control
Technical data
Compound specifications
Survodutide
- Molecular formula
- C192H289N47O61
- Molecular weight
- 4,231.6 Da
- Half-life
- ~7 days (enabling once-weekly dosing)
- Bioavailability
- Optimized for subcutaneous administration with C18 acylation
- CAS number
- 2805997-46-8
Tirzepatide
- Molecular formula
- C225H348N48O68
- Molecular weight
- 4813.45 g/mol
- Half-life
- Approximately 5 days (120 hours)
- Bioavailability
- ~80% (subcutaneous)
- CAS number
- 2023788-19-2
Protocols
Dosing compared
Survodutide
Subcutaneous
- Initiation, part of a 20-week up-titration0.6 mgOnce weekly · Initiation, part of a 20-week up-titrationPhase 2 starting dose; gradual escalation reduces GI side effects [1].
- 26-week maintenance after escalation3.6 mgOnce weekly · 26-week maintenance after escalationMaintenance dose in the phase 2 dose-finding trial; ~12.5% mean weight loss [1].
- 26-week maintenance after escalation4.8 mgOnce weekly · 26-week maintenance after escalationHighest dose studied; up to ~14.9% mean weight loss over 46 weeks [1].
Tirzepatide
Subcutaneous injection
- First 4 weeks2.5 mgOnce weekly · First 4 weeksFDA label starting dose; non-therapeutic, used only to improve GI tolerability before escalating [5]. Inject in abdomen, thigh, or upper arm and rotate sites.
- Increase by 2.5 mg after at least 4 weeks at each dose5-10 mgOnce weekly · Increase by 2.5 mg after at least 4 weeks at each dosePer FDA label, increase to 5 mg after 4 weeks; further increases in 2.5 mg steps no sooner than every 4 weeks as needed [5].
- Ongoing maintenance12.5-15 mgOnce weekly · Ongoing maintenance15 mg is the maximum FDA-labeled dose [5]. SURMOUNT-1 used up to 15 mg weekly for obesity [1].
Applications
Best suited for
Survodutide
- Significant body weight reduction in obesity
- Survodutide is particularly well-suited for individuals focused on significant body weight reduction in obesity. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
- MASH/NASH resolution and liver fibrosis improvement
- Survodutide is particularly well-suited for individuals focused on mash/nash resolution and liver fibrosis improvement. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
- Type 2 diabetes management with concurrent weight loss goals
- Survodutide is particularly well-suited for individuals focused on type 2 diabetes management with concurrent weight loss goals. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
- Enhanced metabolic outcomes through dual receptor engagement
- Survodutide is particularly well-suited for individuals focused on enhanced metabolic outcomes through dual receptor engagement. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Tirzepatide
- People Who Want Maximum Weight Loss Results
- If you're serious about losing significant weight, tirzepatide delivers results that were previously only achievable through bariatric surgery. Clinical trials showed average weight loss exceeding 20% of body weight—that's 50+ pounds for someone starting at 250 pounds. No other medication comes close [1].
- Those Who Haven't Succeeded with Semaglutide
- Thanks to its dual GIP/GLP-1 mechanism, tirzepatide often works better for people who had limited results with GLP-1-only drugs like semaglutide. The added GIP activation provides extra metabolic benefits that can break through plateaus and deliver superior weight loss [2][9].
- People with Type 2 Diabetes Needing Aggressive Control
- Head-to-head trials proved tirzepatide beats semaglutide for blood sugar control. The average HbA1c reduction of over 2 percentage points means many people can dramatically reduce or eliminate other diabetes medications. It's a genuine game-changer for metabolic health [2].
- Individuals Looking to Transform Their Relationship with Food
- Tirzepatide doesn't just reduce hunger—it fundamentally changes how food appeals to you. Users describe feeling free from constant food thoughts, finding it easy to stop eating when satisfied, and losing interest in formerly irresistible treats. It's not willpower—it's biochemistry working for you [11].
Safety profile
Side effects
Survodutide
Common
- Nausea
- Vomiting
- Diarrhea
- Decreased Appetite
Uncommon
- Constipation and Abdominal Pain
Serious
- Acute Pancreatitis
Tirzepatide
Common
- Nausea
- Diarrhea
- Decreased Appetite
- Vomiting
Uncommon
- Gallbladder Problems
- Hair Thinning (Telogen Effluvium)
Serious
- Pancreatitis
- Thyroid Tumors (Theoretical Risk)
Research status
Safety & evidence
Survodutide
- Evidence level
- Strong human trials (Phase 3 or FDA approved)
- FDA status
- Research compound
- Safety overview
- Survodutide data comes from Phase 2 obesity and MASH trials with dose-dependent gastrointestinal side effects (gastrointestinal events in 75% on survodutide vs 42% on placebo in the obesity trial [1]; nausea 66%, diarrhea 49% and vomiting 41% in the MASH trial [6]) that mirror GLP-1 receptor agonist class effects but occur with greater frequency due to additional glucagon receptor activation increasing energy expenditure. Pancreatitis risk exists as with all GLP-1 agonists—baseline lipase evaluation and patient education on warning signs (persistent upper abdominal pain) are essential. Medullary thyroid carcinoma risk, though theoretical based on GLP-1 class, contraindicates use in MEN 2 or personal thyroid cancer history.
Contraindications
- Personal or family history of medullary thyroid carcinoma (GLP-1 class warning)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Known hypersensitivity to survodutide or excipients
- History of pancreatitis (caution advised with GLP-1 receptor agonists)
Tirzepatide
- Evidence level
- Strong human trials (Phase 3 or FDA approved)
- FDA status
- FDA approved for this use
- Safety overview
- Tirzepatide has been extensively studied in the SURPASS (diabetes) and SURMOUNT (obesity) trial programs, involving thousands of participants over multiple years. [1][2][3] The FDA approved it after thorough safety review. [5][6] While GI side effects are common (especially during dose increases), they're typically mild to moderate and improve over time. [5][6] Serious adverse events are rare. The SURPASS-CVOT trial is ongoing to evaluate long-term cardiovascular outcomes. [16]
Contraindications
- Personal or family history of medullary thyroid carcinoma (MTC) [6]
- Multiple Endocrine Neoplasia syndrome type 2 (MEN2) [6]
- History of serious allergic reaction to tirzepatide [6] or any GLP-1/GIP medication
Decision guide
Which is right for you?
Survodutide
Choose Survodutide if…
- Significant body weight reduction in obesity
- MASH/NASH resolution and liver fibrosis improvement
- Type 2 diabetes management with concurrent weight loss goals
- Enhanced metabolic outcomes through dual receptor engagement
Tirzepatide
Choose Tirzepatide if…
- Maximum weight loss results
- Long-term obesity management
- Type 2 diabetes control
- Metabolic health improvement